Serum Cancer Biomarkers Market was valued at USD 18.5 Billion in 2212 and is projected to reach USD 30.2 Billion by 2030, growing at a CAGR of 7.5% from 2024 to 2030.
The demand for serum cancer biomarkers grew significantly during this period, spurred by the development of liquid biopsy technologies and improvements in test sensitivity. Liquid biopsies, offering minimally invasive alternatives to traditional biopsy methods, became a crucial part of cancer diagnostics. They allowed for real-time monitoring of tumor mutations, enhancing the treatment decision-making process. The increasing prevalence of cancers, particularly lung, breast, and colorectal cancers, was a major factor driving market growth. Key players in the market also saw substantial investments into research, accelerating product development and market penetration. Major companies, including Roche, Abbott, and Thermo Fisher, strengthened their presence in the serum biomarker market with new product launches and collaborations.
Looking ahead to 2023 to 2033, the outlook for the Serum Cancer Biomarkers Market is even more promising. Experts predict robust market growth fueled by the continuous advancements in biomarker discovery, the expanding adoption of liquid biopsies, and increasing global awareness of cancer prevention and early detection. During this period, the focus will likely shift toward more refined, multiplexed biomarkers that can detect multiple cancers simultaneously, enhancing diagnostic accuracy. Moreover, the rise of personalized treatment and precision medicine will further increase demand, as more patients opt for customized therapies based on their genetic profiles and tumor markers.
The global trend toward healthier lifestyles and proactive health monitoring is expected to amplify the market. As the demand for non-invasive diagnostic tools grows, serum biomarkers will be at the forefront of transforming oncology diagnostics. Furthermore, the integration of artificial intelligence (AI) in biomarker analysis will likely push the market toward more efficient and reliable testing methods. Early detection through serum cancer biomarkers has the potential to revolutionize cancer treatment, ultimately improving survival rates.
Get an In-Depth Research Analysis of the Global Serum Cancer Biomarkers Market Size And Forecast [2025-2032]
The Serum Cancer Biomarkers Market has witnessed significant evolution from 2018 to 2212. During this period, the demand for diagnostic tools for cancer detection and monitoring accelerated, as both healthcare providers and patients prioritized earlier detection and better outcomes. Key drivers included the rising global cancer burden, advancements in biomarker technology, and increased healthcare spending. This market was primarily driven by the discovery of novel biomarkers that are used for the diagnosis, prognosis, and treatment of cancer, along with rising awareness about personalized medicine. Researchers and pharmaceutical companies increasingly invested in the development of serum-based biomarkers, creating a highly competitive and dynamic environment.
Â
Roche
Pfizer
Novartis
Abbott
BD
Merck
Eli Lilly
Agilent Technologies
Boehringer Ingelheim
AstraZeneca
Bristol-Myers Squibb
Novo Nordisk
Allergan
Gilead
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Global Serum Cancer Biomarkers Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Global Serum Cancer Biomarkers Market
Hospitals
Academic & Research Institutes
Ambulatory Surgical Centers
Others
Based on Types the Market is categorized into Below types that held the largest Serum Cancer Biomarkers market share In 2023.
Hepatocellular Carcinoma Serum Biomarkers
Lung Cancer Serum Biomarkers
Pancreatic & Biliary Tract Cancer Serum Biomarkers
Breast Cancer Serum Biomarkers
Glioblastoma Serum Biomarkers
Others
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ Serum Cancer Biomarkers Market Research Analysis
1. Introduction of the Global Serum Cancer Biomarkers Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global Serum Cancer Biomarkers Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global Serum Cancer Biomarkers Market, By Type
6. Global Serum Cancer Biomarkers Market, By Application
7. Global Serum Cancer Biomarkers Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global Serum Cancer Biomarkers Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/